Odey Asset Management Group LTD Has Upped By $1.60 Million Its Regeneron Pharmaceuticals (REGN) Holding; J Sainsbury plc (LON:SBRY) Had 7 Bulls

October 13, 2017 - By Clifton Ray

Odey Asset Management Group Ltd increased Regeneron Pharmaceuticals (REGN) stake by 102.09% reported in 2017Q2 SEC filing. Odey Asset Management Group Ltd acquired 3,267 shares as Regeneron Pharmaceuticals (REGN)’s stock rose 21.24%. The Odey Asset Management Group Ltd holds 6,467 shares with $3.18 million value, up from 3,200 last quarter. Regeneron Pharmaceuticals now has $47.45B valuation. The stock declined 0.96% or $4.29 reaching $442.86 on the news. About 488,158 shares traded. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 17.40% since October 13, 2016 and is uptrending. It has outperformed by 0.70% the S&P500.

Among 20 analysts covering Sainsbury J PLC (LON:SBRY), 7 have Buy rating, 3 Sell and 10 Hold. Therefore 35% are positive. Sainsbury J PLC had 230 analyst reports since July 24, 2015 according to SRatingsIntel. The company was maintained on Friday, November 13 by Barclays Capital. The firm earned “Buy” rating on Thursday, May 5 by Deutsche Bank. BNP Paribas maintained J Sainsbury plc (LON:SBRY) rating on Friday, August 5. BNP Paribas has “Outperform” rating and GBX 260 target. On Monday, September 28 the stock rating was maintained by Deutsche Bank with “Hold”. The stock of J Sainsbury plc (LON:SBRY) has “Reduce” rating given on Friday, June 3 by HSBC. The stock of J Sainsbury plc (LON:SBRY) has “Buy” rating given on Wednesday, July 27 by Deutsche Bank. The firm has “Neutral” rating given on Wednesday, March 16 by Nomura. BNP Paribas maintained it with “Outperform” rating and GBX 255 target in Monday, January 9 report. Nomura maintained J Sainsbury plc (LON:SBRY) rating on Monday, March 21. Nomura has “Neutral” rating and GBX 280 target. The stock of J Sainsbury plc (LON:SBRY) earned “Reduce” rating by HSBC on Wednesday, June 1. See J Sainsbury plc (LON:SBRY) latest ratings:

03/10/2017 Broker: Berenberg Rating: Buy New Target: GBX 300.00 Initiates Starts
02/10/2017 Broker: Credit Suisse Rating: Outperform Old Target: GBX 320.00 New Target: GBX 295.00 Maintain
28/09/2017 Broker: Deutsche Bank Rating: Hold Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
20/09/2017 Broker: Citigroup Rating: Buy Old Target: GBX 305.00 New Target: GBX 305.00 Maintain
20/09/2017 Broker: Deutsche Bank Rating: Hold Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
13/09/2017 Broker: BNP Paribas Rating: Neutral Old Target: GBX 250.00 New Target: GBX 250.00 Maintain
06/09/2017 Broker: HSBC Rating: Reduce Maintain
01/09/2017 Broker: Barclays Capital Rating: Equal Weight Old Target: GBX 260.00 New Target: GBX 240.00 Maintain
29/08/2017 Broker: Credit Suisse Rating: Outperform Old Target: GBX 320.00 New Target: GBX 320.00 Maintain
22/08/2017 Broker: Shore Capital Rating: Buy Maintain

Among 28 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 13 have Buy rating, 1 Sell and 14 Hold. Therefore 46% are positive. Regeneron Pharmaceuticals Inc. had 89 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Sell” rating by Robert W. Baird on Thursday, September 7. Oppenheimer maintained the stock with “Hold” rating in Wednesday, September 27 report. The rating was maintained by Morgan Stanley on Friday, October 6 with “Equal-Weight”. Oppenheimer maintained the shares of REGN in report on Wednesday, June 14 with “Hold” rating. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned “Underperform” rating by Robert W. Baird on Tuesday, August 1. The rating was maintained by BMO Capital Markets on Monday, September 11 with “Hold”. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned “Market Perform” rating by Bernstein on Monday, June 26. Chardan Capital Markets upgraded the shares of REGN in report on Tuesday, February 16 to “Neutral” rating. Credit Suisse upgraded it to “Buy” rating and $48500 target in Thursday, August 3 report. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has “Sell” rating given on Monday, November 7 by Chardan Capital Markets.

Odey Asset Management Group Ltd decreased Grupo Financiero Galicia S A (NASDAQ:GGAL) stake by 15,974 shares to 215,524 valued at $9.19M in 2017Q2. It also reduced Cadiz Inc (NASDAQ:CDZI) stake by 33,268 shares and now owns 1.27 million shares. Amaya Inc (AMYGF) was reduced too.

Investors sentiment increased to 1.38 in 2017 Q2. Its up 0.12, from 1.26 in 2017Q1. It improved, as 42 investors sold REGN shares while 157 reduced holdings. 84 funds opened positions while 190 raised stakes. 71.53 million shares or 1.38% more from 70.55 million shares in 2017Q1 were reported. Endurance Wealth Management has 0% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Moreover, American Money Ltd Limited Liability Company has 0.26% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 750 shares. Cohen Lawrence B holds 600 shares or 0.19% of its portfolio. Pub Sector Pension Board holds 8,597 shares or 0.04% of its portfolio. Reliance Tru Of Delaware reported 1,461 shares. Invesco Ltd has invested 0.14% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Barometer Capital Mngmt Incorporated holds 0.63% or 12,710 shares. The New York-based Adirondack Tru Comm has invested 0.04% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Us Bank & Trust De has 0.01% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 5,145 shares. Dekabank Deutsche Girozentrale has invested 0.31% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). 1,966 were accumulated by Pitcairn. Creative Planning invested in 13,705 shares or 0.03% of the stock. Fiera Corporation has invested 0.01% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Telemus Capital Limited Liability Corporation stated it has 0.27% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Mitsubishi Ufj Secs Ltd owns 180 shares.

Since May 12, 2017, it had 1 buying transaction, and 7 insider sales for $42.75 million activity. Shares for $4.01M were sold by STAHL NEIL. BROWN MICHAEL S sold $948,890 worth of stock or 2,000 shares. $65.06 million worth of stock was bought by Sanofi on Friday, June 2. GOLDSTEIN JOSEPH L also sold $482,550 worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Friday, June 9. $4.26M worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was sold by VAGELOS P ROY. 21,147 Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares with value of $9.90M were sold by Terifay Robert J.

J Sainsbury plc is engaged in grocery-related retailing and retail banking. The company has market cap of 5.28 billion GBP. The Company’s divisions include Retailing; Financial services, and Property investments. It has a 13.88 P/E ratio. The Retailing segment is engaged in the operation of supermarkets and convenience.

The stock increased 0.47% or GBX 1.13 on October 13, reaching GBX 241.13. About 4.62 million shares traded. J Sainsbury plc (LON:SBRY) has 0.00% since October 13, 2016 and is . It has underperformed by 16.70% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com